| B I O CHEMI S TRY
Under physiological conditions, cellular uptake and metabolic conversion regulates ADO extracellular concentrations. This process is rapid (seconds) and restricts ADO actions to local tissues and cellular sites where it is released. 11, 12 Adenosine kinase (AK, ATP:adenosine 5′-phosphotransferase, EC 2.7.1.20) is a cytosolic enzyme that catalyzes the phosphorylation of ADO to AMP and is one of the two enzymes responsible for ADO metabolism. ADO deaminase (ADA, adenosine aminohydrolase, EC 3.5.4.4) also contributes to ADO conversion, but AK-mediated metabolism of ADO is the primary regulator under physiologic conditions. 13 The mammalian AK enzyme has been cloned 14, 15 and crystallized. 16 Differential splicing and promoter activity results in two mammalian isoforms of AK, termed long and short, that differ based on the length of exon 1. 17 These isoforms are also differentially localized in the intracellular compartment with the long form found in the nucleus and the short form in the cytoplasm. 17 While the physiological significance of the specific isoforms remains to be determined, a role for nuclear AK in transmethylation reactions has been proposed. 17 Functional AK contains two ADO binding sites, a catalytic site with high affinity for ADO and a lower affinity regulatory MgATP 2-binding site. 18, 19 Extracellular ADO concentrations are governed by an ADO-specific transport system that operates as a non-concentrative, bidirectional, facilitated diffusion transporter. Thus, AK inhibition has the net effect of decreasing cellular reuptake of ADO resulting in an increase in the local concentration of ADO in the extracellular compartment. 20 The molecular biology, enzymology, and biochemistry of AK have been comprehensively reviewed. 17 
| PHYS IOLOGY
The dynamic intracellular regulation of ADO by AK supports a mechanistic hypothesis that the intracellular blockade of AK may effectively enhance extracellular ADO concentrations in cells 30 Additionally, an A 2A receptor antagonist has been approved in Japan for the management of Parkinsonian symptoms. 30 A primary limiting factor in the advancement of ADO-based therapeutics is the fact that ADO modulation is highly relevant in essentially all organ systems such that mechanism-based peripheral or central side-effects or tolerability issues are difficult to avoid or modulate. 6, 27 Given the ubiquity of homeostatic ADO modulation of physiological systems, the hypothesis regarding the site and event specificity afforded by inhibition of AK 22, 23 represented a viable therapeutic approach that offered the potential for improved benefit/risk profile as compared to direct-acting agonists. Importantly, systemically administered AK inhibitors were found to exert therapeutic effects (ie, anti-hyperalgesia) at 3-to 10-fold lower doses than those causing alterations in psychomotor performance (eg, exploratory motor activity or rotorod performance) and cardiovascular (eg, blood pressure and heart rate) as compared to directacting agonists (Table 3 ).
| SAFE T Y ISSUE S
The preclinical profile of AK inhibitors to alleviate hyperexcitability in experimental models of seizure disorders and chronic pain without Note: Data from. 35 Locomotor activity, exploratory motor activity 0-30 min; Rotorod, 60 min pretreatment; Thermal Hyperalgesia, carrageenan-induced hyperalgesia. 
| TOXICOLOGY SUMMARY
Early toxicological studies revealed that the non-nucleoside AK inhibitor, ABT-702, possessed clastogenic activity that was idiosyncratic to this molecule but not to other members of this class of pyridopyrimidine AK inhibitors. 39, 47 While not clastogenic, the clinical development of nucleoside-based AK inhibitors including clinical candidates structurally related to GP-3269 was also stopped due to toxicological signals discovered in subchronic dosing studies. of the offspring which was attributed to deleterious effects on thermoregulation, respiration, and liver toxicology. 17 Additionally, some ribose-containing AK inhibitors have also been reported to be lethal following chronic administration of antinociceptive doses in rats. 48 The findings described above are based on the author's notes, personal communications, and the limited available literature and thus should be considered anecdotal. That said, these toxicological findings were observed by two independent groups. Both the severity of the potential harms and lack of reliable clinical biomarkers or predictability in humans led both drug discovery groups to independently discontinue further research efforts to develop AK inhibitors as therapeutic agents. Taken together, the available information regarding the toxicology readouts produced by potent and selective pharmacological blockade of AK indicates that continued optimization of these or similar molecules is unlikely to yield therapeutically useful interventions. Several groups have renewed research into the structure activity relationships of structurally novel AK inhibitors. 41, 43, 46 However, these new AK inhibitor chemotypes do not appear to either pharmacologically or enzymatically differentiate from the previously described highly potent AK inhibitors. 5 Furthermore, all known small molecule AK inhibitors do not differentiate between short and long forms of AK and further research is needed to determine if selective modulation of cytoplasmic or nuclear AK is biochemically feasible or would lead to physiologically important effects unrelated to downstream activation of ADO receptors. 17 One potential experimental approach to address such questions might be the further interrogation of
